Status:
COMPLETED
Lidocaine Versus Duloxetine for the Prevention of Taxane-Induced Peripheral Neuropathy In Breast Cancer Patients
Lead Sponsor:
Gamal Mohamed Taha Abouelmagd
Conditions:
Peripheral Neuropathy
Chemotherapy-induced Peripheral Neuropathy
Eligibility:
FEMALE
18-65 years
Phase:
NA
Brief Summary
The aim of the study is to evaluate the effect of intravenous (IV) lidocaine versus oral duloxetine on the onset and severity of TIPN in patient with breast cancer as well as evaluation of Patients' q...
Detailed Description
Patients' assessment: * Medical history (Previous diseases and medications) * Clinical examination and laboratory investigations (according to patient' condition). * Each patient will be informed wit...
Eligibility Criteria
Inclusion
- breast cancer
- at any stage,
- Taxane chemo-protocol.
Exclusion
- Documented history of gloves and stock neuropathy.
- Alcohol abuse.
- Abnormal renal or liver function tests.
- Allergy to local anesthetics.
- Myocardial infarction within 6 months
- Profound high-grade arrhythmias.
- Patients with neurological or psychological problems.
- Diabetes Mellitus.
- History of previous chemotherapy treatment
Key Trial Info
Start Date :
January 15 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 5 2022
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04732455
Start Date
January 15 2021
End Date
July 5 2022
Last Update
July 11 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Egypt Medical Research Institute
Alexandria, Egypt